Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G-DISCOTEQ for BCG-unresponsive non-muscle-invasive bladder cancer
ACTRN12626000234314Phase 2Not yet recruiting
- Sponsor
- South Metropolitan Health Service
- Start
- Apr 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of gemcitabine and docetaxel in non-muscle-invasive bladder cancer (NMIBC) (2 cohorts), sponsored by South Metropolitan Health Service. Primary endpoint: Complete response rate. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
gemcitabinedocetaxel
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on ACTRN12626000234314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000234314.